Swedish Orphan Biovitrum Yönetim

Yönetim kriter kontrolleri 3/4

Swedish Orphan Biovitrum CEO'su Guido Oelkers, May2017 tarihinde atandı, in görev süresi 7.5 yıldır. in toplam yıllık tazminatı SEK 48.88M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.1% maaş ve 74.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler SEK 138.98M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 4 yıldır.

Anahtar bilgiler

Guido Oelkers

İcra Kurulu Başkanı

SEK 48.9m

Toplam tazminat

CEO maaş yüzdesi	25.1%
CEO görev süresi	7.5yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26

CEO Tazminat Analizi

Guido Oelkers'un ücretlendirmesi Swedish Orphan Biovitrum'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	SEK 4b
Jun 30 2024	n/a	n/a	SEK 2b
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 49m	SEK 12m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 3b
Jun 30 2023	n/a	n/a	SEK 3b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 47m	SEK 11m	SEK 3b
Sep 30 2022	n/a	n/a	SEK 2b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 42m	SEK 10m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 3b
Mar 31 2021	n/a	n/a	SEK 3b
Dec 31 2020	SEK 33m	SEK 10m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 3b
Mar 31 2020	n/a	n/a	SEK 4b
Dec 31 2019	SEK 33m	SEK 10m	SEK 3b
Sep 30 2019	n/a	n/a	SEK 3b
Jun 30 2019	n/a	n/a	SEK 3b
Mar 31 2019	n/a	n/a	SEK 3b
Dec 31 2018	SEK 26m	SEK 9m	SEK 2b
Sep 30 2018	n/a	n/a	SEK 2b
Jun 30 2018	n/a	n/a	SEK 2b
Mar 31 2018	n/a	n/a	SEK 1b
Dec 31 2017	SEK 16m	SEK 5m	SEK 1b

Tazminat ve Piyasa: Guido 'nin toplam tazminatı ($USD 4.52M ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.61M ).

Tazminat ve Kazançlar: Guido 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Guido Oelkers (59 yo)

7.5yrs

Görev süresi

SEK 48,883,000

Tazminat

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Guido Oelkers	CEO & President	7.5yrs	SEK 48.88m	0.12% SEK 138.3m
Henrik Stenqvist	Chief Financial Officer	6.3yrs	Veri yok	0.016% SEK 18.2m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.8yrs	Veri yok	0.0089% SEK 9.9m
Daniel Rankin	Head of Strategy & Corporate Development	2.8yrs	Veri yok	0.0029% SEK 3.2m
Lena Bjurner	Head of Human Resources	1.8yrs	Veri yok	Veri yok
Armin Reininger	Senior Scientific & Medical Advisor	7.8yrs	Veri yok	0.0047% SEK 5.2m
Norbert Oppitz	Head of International	7.1yrs	Veri yok	0.012% SEK 12.9m
Sofiane Fahmy	Head of Europe	5.8yrs	Veri yok	0.0077% SEK 8.6m
Duane Barnes	Head of North America	3.8yrs	Veri yok	Veri yok
Mahmood Ladha	Head of Strategic Transformation Operations	no data	Veri yok	0.0018% SEK 2.0m
Christine Wesstrom	Head of Technical Operations	2.7yrs	Veri yok	0.0032% SEK 3.6m
Lydia Abad-Franch	Senior VP	1.8yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: SOBI 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hans Wigzell	Chairman of Scientific Advisory Board	23.8yrs	SEK 158.00k	Veri yok
Helena Saxon	Director	13.6yrs	SEK 828.00k	0.0067% SEK 7.4m
Anders Ullman	Director	1.5yrs	SEK 463.00k	0.0010% SEK 1.1m
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ralf Pettersson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stefan Del Prato	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Annette Clancy	Independent Chairman	10.5yrs	SEK 770.00k	0.00099% SEK 1.1m
Staffan Schuberg	Independent Director	4.5yrs	SEK 827.00k	0.0021% SEK 2.3m
Filippa Stenberg	Director	3.5yrs	SEK 673.00k	0.00017% SEK 189.0k
Katy Mazibuko	Employee Representative Director	1.8yrs	Veri yok	0.0013% SEK 1.4m
Christophe Bourdon	Independent Director	1.5yrs	SEK 433.00k	Veri yok

4.0yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SOBI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Swedish Orphan Biovitrum Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

CEO & President recently sold kr29m worth of stock

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Recent updates

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

Investor sentiment improves as stock rises 15%

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

CEO & President recently sold kr29m worth of stock

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 21%

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well